We are excited to be launching our new email newsletter series! Twice a month, we’ll be reaching out to you with key topics that impact your global business.
Below, we offer three of the topics that we’ll be touching on regularly. We’ll expand upon our thoughts in our blog, and we invite you to reply here or on the blog with your own thoughts and ideas.
The MedWorld Strategic Connection
Exit Strategies for Emerging Technology
| If you are seeking a possible exit with a “Big S” (Fortune 500 Multi-National Company “MNC”), there are some key factors for you to consider which may vary slightly from an exit for a P.E. or for IPO. For example, the “team” is critical for an IPO or for a P.E. as investors number one criteria for investment is “team”. However, the Big S companies have very experienced teams in place and often want to do things “their way,” so the seller’s team is less important in this scenario. What becomes “critical to success” are items including (1) Freedom to Operate (FTO); (2) IP Patents Filed (and Approved); (3) Clinical Validation; (4) Market opportunity for unmet clinical needs addressed by your solution; (5) Regulatory Clearances, and (6) Reimbursement Pathways. Click here to get a better idea on how the “Big S” think when looking at a Medtech Startup. | |
Related
